Igor Samoylenko

Talimogene laherparepvec upregulates immune-cell populations in non-injected lesions: findings from a phase II, multicenter, open-label study in patients with stage IIIB–IVM1c melanoma

Josep Malvehy, Igor Samoylenko, Dirk Schadendorf et al. · Journal for ImmunoTherapy of Cancer · 2021 · 73 citations · Full text

Measuring Intratumoral Heterogeneity of Immune Repertoires

Diana V. Yuzhakova, Lilia N. Volchkova, Mikhail V. Pogorelyy et al. · Frontiers in Oncology · 2020 · 19 citations · Full text

Real-World Experience with Targeted Therapy in BRAF Mutant Advanced Melanoma Patients: Results from a Multicenter Retrospective Observational Study Advanced Melanoma in Russia (Experience) (ADMIRE)

Kristina V. Orlova, Evgeniy V. Ledin, Natalia V. Zhukova et al. · Cancers · 2021 · 17 citations · Full text

Real-world Experience, Cancer Management, Immunology +16

LBA41 Long-term survival with neoadjuvant therapy in melanoma: Updated pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)

G.V. Long, C.U. Blank, R. Amaria et al. · Annals of Oncology · 2024 · 17 citations

Talimogene laherparepvec (T-VEC) treatment increases intratumoral effector T-cell and natural killer (NK) cell density in noninjected tumors in patients (pts) with stage IIIB–IVM1c melanoma: Evidence for systemic effects in a phase II, single-arm study

Helen Gogas, Igor Samoylenko, Dirk Schadendorf et al. · Annals of Oncology · 2018 · 16 citations · Full text